Related Experiment Video
Updated: May 5, 2026

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
Published on: January 22, 2017
Does reduced creatine synthesis protect against statin myopathy?
Kevin D Ballard1, Paul D Thompson
1Division of Cardiology, Henry Low Heart Center, Hartford Hospital, Hartford, CT 06102, USA.
Statins can cause muscle problems (myopathy). A gene variant reducing creatine production is linked to less statin myopathy, suggesting creatine may protect against this side effect.
Area of Science:
- Biochemistry
- Pharmacology
- Genetics
Background:
- Statins are primary drugs for lowering cholesterol.
- Statin-induced myopathy is a significant adverse effect.
- Glycine amidinotransferase (GATM) regulates creatine biosynthesis.
Purpose of the Study:
- To investigate the role of creatine biosynthesis in statin-induced myopathy.
- To explore the protective potential of reduced creatine production against statin myopathy.
Main Methods:
- Analysis of genetic data linking single nucleotide polymorphisms to statin myopathy.
- Examination of the association between GATM gene expression and myopathy incidence.
- Biochemical pathway analysis of creatine biosynthesis.
Main Results:
- A specific single nucleotide polymorphism associated with decreased GATM expression was identified.
- This GATM polymorphism showed a correlation with reduced incidence of statin-induced myopathy.
- Reduced expression of the creatine biosynthesis enzyme GATM is linked to lower risk of statin myopathy.
Conclusions:
- Reduced creatine production may offer protection against statin-induced myopathy.
- Targeting creatine biosynthesis could be a novel therapeutic strategy for managing statin side effects.
- Further research is warranted to confirm the protective role of creatine.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Satellite Stem Cells and Muscular Dystrophy
Muscle Recovery and Fatigue
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Atherosclerosis III: Management
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

